Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors while in the central nervous process, conolidine modulates alternate molecular targets. A Science Innovations review identified that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid https://popec665nmm6.goabroadblog.com/profile